Protalix Biotherapeutics (PLX) Stock Price, Quote & News

Company Profile

Protalix BioTherapeutics, Inc., a biopharmaceutical company, engages in the development, production, and commercialization of recombinant therapeutic proteins based on the ProCellEx plant cell-based protein expression system. The company offers Elelyso for the treatment of Gaucher disease; and Elfabrio for the treatment of adult patients with a confirmed diagnosis of Fabry disease. It is also developing PRX-115, a plant cell expressed recombinant PEGylated Uricase, which is in Phase 2 trial for...

Industry: Biotechnology

Sector: Healthcare

Phone: 201 696 9345

Website: www.protalix.com

Address:

2 University Plaza, Suite 100, Hackensack, United States

SKL05 Feb. 4 at 7:33 PM

$PLX yes, selling at $3 was the right call the last two times we been there. But look at the chart and the fundamentals. We are going to $5 easily

0 · Reply

brunoq14 Feb. 4 at 7:29 PM

$PLX And we still have the decision date and the milestone announcement.

0 · Reply

Kgra Feb. 4 at 7:28 PM

$PLX cooooom on $3

0 · Reply

smartmoney43 Feb. 4 at 7:24 PM

$PLX 😍😍

0 · Reply

zoomlik Feb. 4 at 7:12 PM

$PLX What is our label for 4wk? $6BY years end

1 · Reply

Thinkapp Feb. 4 at 7:11 PM

$PLX better to hold since it is too close to official approval and 25m milestone.

0 · Reply

EaglePrime Feb. 4 at 7:08 PM

’Join Starlight ⬇️ A premium small-cap value community. Free for now, with limited availability🌟 _also watching these>>> $CLW $MTEN $PLX $AXL

0 · Reply

Chrille20 Feb. 4 at 6:59 PM

$PLX good so far

0 · Reply

PLX_BULLS Feb. 4 at 6:58 PM

$PLX 2.97 on deck!

0 · Reply

Thinkapp Feb. 4 at 6:55 PM

$PLX what?

0 · Reply

A March Decision That Could Change Protalix BioTherapeutics Outlook

Jan 30, 2026, 9:47 AM EST - 5 days ago

Chiesi Global Rare Diseases and Protalix BioTherapeutics Receive Positive CHMP Opinion for an Additional Dosing Regimen of Every Four Weeks for Elfabrio® (pegunigalsidase alfa) in the EU

Jan 30, 2026, 9:47 AM EST - 5 days ago

Chiesi Global Rare Diseases and Protalix BioTherapeutics Receive Positive CHMP Opinion for an Additional Dosing Regimen of 2mg/kg Body Weight Every-Four-Weeks for Elfabrio® (pegunigalsidase alfa) ▼ in the EU

Jan 5, 2026, 6:50 AM EST - 4 weeks ago

Protalix BioTherapeutics Letter to Stockholders

Dec 17, 2025, 6:50 AM EST - 7 weeks ago

Protalix Biotherapeutics and Secarna Pharmaceuticals Enter into Collaboration and Option Agreement

Nov 13, 2025, 10:11 AM EST - 2 months ago

Protalix BioTherapeutics, Inc. (PLX) Q3 2025 Earnings Call Transcript

Nov 13, 2025, 6:50 AM EST - 2 months ago

Protalix BioTherapeutics Reports Third Quarter 2025 Financial and Business Results

Nov 6, 2025, 6:50 AM EST - 3 months ago

Protalix BioTherapeutics to Announce Third Quarter 2025 Financial and Business Results on November 13, 2025

Nov 5, 2025, 10:50 AM EST - 3 months ago

PLX Investors Have Opportunity to Join Protalix BioTherapeutics, Inc. Fraud Investigation with the Schall Law Firm

Nov 3, 2025, 4:30 PM EST - 3 months ago

Chiesi Global Rare Diseases and Protalix BioTherapeutics Seek Re-examination from the EMA for the Negative Opinion for Elfabrio (pegunigalsidase alfa) Alternative Dosing Regimen of Every Four Weeks in the EU

Oct 17, 2025, 11:23 AM EDT - 3 months ago

Why Is Protalix BioTherapeutics Stock Falling On Friday?

Oct 17, 2025, 6:58 AM EDT - 3 months ago

Chiesi Global Rare Diseases and Protalix Biotherapeutics Acknowledge CHMP Negative Opinion on Every Four Week Dosing Regimen of Elfabrio® (pegunigalsidase alfa) in the EU

Sep 11, 2025, 10:55 AM EDT - 5 months ago

Protalix BioTherapeutics to Present at Investor Summit Virtual

Sep 2, 2025, 6:50 AM EDT - 5 months ago

Protalix BioTherapeutics to Present at the H.C. Wainwright 27th Annual Global Investment Conference

Aug 25, 2025, 6:57 AM EDT - 5 months ago

Protalix: Speculative Buy On Promising Plant-Cell Platform And Elfabrio Ramp

Aug 14, 2025, 12:47 PM EDT - 6 months ago

Protalix BioTherapeutics, Inc. (PLX) Q2 2025 Earnings Call Transcript

Aug 14, 2025, 6:50 AM EDT - 6 months ago

Protalix BioTherapeutics Reports Second Quarter 2025 Financial and Business Results

Aug 7, 2025, 12:53 PM EDT - 6 months ago

Protalix BioTherapeutics to Announce Second Quarter 2025 Financial and Business Results on August 14, 2025

Jul 21, 2025, 6:50 AM EDT - 7 months ago

Protalix BioTherapeutics Appoints Gilad Mamlok as its New Senior Vice President and Chief Financial Officer

Jun 30, 2025, 6:50 AM EDT - 7 months ago

Protalix BioTherapeutics Added to Russell 3000® and 2000 Indexes®

May 14, 2025, 6:50 AM EDT - 9 months ago

Protalix BioTherapeutics to Present at the 3rd Annual H.C. Wainwright BioConnect Investor Conference at Nasdaq NYC

May 9, 2025, 4:12 PM EDT - 9 months ago

Protalix BioTherapeutics, Inc. (PLX) Q1 2025 Earnings Call Transcript

May 9, 2025, 6:50 AM EDT - 9 months ago

Protalix BioTherapeutics Reports First Quarter 2025 Financial and Business Results

May 5, 2025, 6:50 AM EDT - 9 months ago

Protalix BioTherapeutics to Announce First Quarter 2025 Financial and Business Results on May 9, 2025

Apr 10, 2025, 9:54 AM EDT - 10 months ago

Protalix BioTherapeutics Is A Strong Buy With Increasing Revenues And A Promising Pipeline

Mar 24, 2025, 6:50 AM EDT - 11 months ago

Protalix BioTherapeutics to Present at the iAccess Alpha Virtual Best Ideas Spring Conference 2025

Mar 17, 2025, 11:56 AM EDT - 11 months ago

Protalix BioTherapeutics Says With Debt Fully Repaid, It's Well-Positioned To Execute Strategy Through 2025 And Beyond

Mar 17, 2025, 10:22 AM EDT - 11 months ago

Protalix BioTherapeutics, Inc. (PLX) Q4 2024 Earnings Call Transcript

Mar 17, 2025, 6:50 AM EDT - 11 months ago

Protalix BioTherapeutics Reports Fiscal Year 2024 Financial and Business Results

Mar 10, 2025, 6:50 AM EDT - 11 months ago

Protalix BioTherapeutics to Announce Fiscal Year 2024 Financial and Business Results on March 17, 2025

Feb 4, 2025, 6:50 AM EST - 1 year ago

Protalix BioTherapeutics to Participate in the 2025 BIO CEO & Investor Conference

Dec 23, 2024, 6:50 AM EST - 1 year ago

Protalix BioTherapeutics Issues 2025 Letter to Stockholders

Dec 9, 2024, 6:30 AM EST - 1 year ago

Chiesi Global Rare Diseases and Protalix BioTherapeutics Announce Validation of Variation Submission by European Medicines Agency for pegunigalsidase alfa

Nov 14, 2024, 11:23 AM EST - 1 year ago

Protalix BioTherapeutics, Inc. (PLX) Q3 2024 Earnings Call Transcript

Nov 14, 2024, 6:50 AM EST - 1 year ago

Protalix BioTherapeutics Reports Third Quarter 2024 Financial and Business Results

Nov 7, 2024, 6:50 AM EST - 1 year ago

Protalix BioTherapeutics to Announce Third Quarter 2024 Financial and Business Results on November 14, 2024

Oct 25, 2024, 7:18 AM EDT - 1 year ago

Protalix BioTherapeutics to Present Phase I PRX-115 Data in Late-Breaking Poster at ACR Convergence 2024

Sep 17, 2024, 8:00 AM EDT - 1 year ago

Kaskela Law LLC Announces Shareholder Investigation of Protalix BioTherapeutics, Inc. (NYSE: PLX) and Encourages Investors to Contact the Firm

Sep 16, 2024, 8:35 AM EDT - 1 year ago

Protalix BioTherapeutics to Present at the Life Sciences Investor Forum September 19, 2024

Sep 4, 2024, 6:50 AM EDT - 1 year ago

Protalix BioTherapeutics to Present at the H.C. Wainwright 26th Annual Global Investment Conference

Sep 3, 2024, 6:50 AM EDT - 1 year ago

Protalix BioTherapeutics Announces Repayment of Outstanding Senior Secured Convertible Promissory Notes

Aug 14, 2024, 10:32 AM EDT - 1 year ago

Protalix BioTherapeutics, Inc. (PLX) Q2 2024 Earnings Call Transcript

Aug 14, 2024, 6:50 AM EDT - 1 year ago

Protalix BioTherapeutics Reports Second Quarter 2024 Financial and Business Results

Aug 7, 2024, 6:50 AM EDT - 1 year ago

Protalix BioTherapeutics to Announce Second Quarter 2024 Financial and Business Results on August 14, 2024

Jun 13, 2024, 6:50 AM EDT - 1 year ago

Protalix BioTherapeutics to Host In-Person Investor Day to Discuss Current Treatment Landscapes and Clinical Results for Fabry Disease and Uncontrolled Gout

May 29, 2024, 8:38 AM EDT - 1 year ago

Protalix BioTherapeutics to Present at the 2024 BIO International Convention

May 10, 2024, 11:13 AM EDT - 1 year ago

Protalix BioTherapeutics, Inc. (PLX) Q1 2024 Earnings Call Transcript

May 10, 2024, 6:50 AM EDT - 1 year ago

Protalix BioTherapeutics Reports First Quarter 2024 Financial and Business Results

SKL05 Feb. 4 at 7:33 PM

$PLX yes, selling at $3 was the right call the last two times we been there. But look at the chart and the fundamentals. We are going to $5 easily

0 · Reply

brunoq14 Feb. 4 at 7:29 PM

$PLX And we still have the decision date and the milestone announcement.

0 · Reply

Kgra Feb. 4 at 7:28 PM

$PLX cooooom on $3

0 · Reply

smartmoney43 Feb. 4 at 7:24 PM

$PLX 😍😍

0 · Reply

zoomlik Feb. 4 at 7:12 PM

$PLX What is our label for 4wk? $6BY years end

1 · Reply

Thinkapp Feb. 4 at 7:11 PM

$PLX better to hold since it is too close to official approval and 25m milestone.

0 · Reply

EaglePrime Feb. 4 at 7:08 PM

’Join Starlight ⬇️ A premium small-cap value community. Free for now, with limited availability🌟 _also watching these>>> $CLW $MTEN $PLX $AXL

0 · Reply

Chrille20 Feb. 4 at 6:59 PM

$PLX good so far

0 · Reply

PLX_BULLS Feb. 4 at 6:58 PM

$PLX 2.97 on deck!

0 · Reply

Thinkapp Feb. 4 at 6:55 PM

$PLX what?

0 · Reply

BryGuy29 Feb. 4 at 6:53 PM

$PLX I’m starting to fall in love with this stock again. Like high school sweethearts getting back together after breaking up. 😂

3 · Reply

vyparik1 Feb. 4 at 6:52 PM

$PLX 🚀🚀🚀

0 · Reply

osubuck30 Feb. 4 at 6:00 PM

$PLX lol… it’s called institution algo accumulation mode

1 · Reply

pennyman Feb. 4 at 5:37 PM

$PLX The stock price has shown a nice increase and I think it may continue unless something negative is announced. I own many of the $2.50 call options and today I am buying the $5 5-15 call options as they are cheap enough with the profits I have in the $2.50 calls. Time will tell. JMO GLTA

0 · Reply

Funmoney2 Feb. 4 at 5:34 PM

$PLX some explain why when price is 2.90 share lots available keep getti g higher. Doesnt that signify people are trying to take profits and if thats the case they are srlling and not buying more

0 · Reply

randallb Feb. 4 at 5:22 PM

$PLX BREAKOUT see you at $10 later this year.

1 · Reply

dannymac65 Feb. 4 at 5:17 PM

$PLX This is the new battle. The spoof ask blocks moved up to 2.95 and 2.96.

0 · Reply

pmcd777 Feb. 4 at 5:16 PM

$PLX aaaaannnnnd we are there! Now what? 😁

1 · Reply

pmcd777 Feb. 4 at 5:16 PM

$PLX hit 2.895!

0 · Reply

crackpot Feb. 4 at 4:45 PM

$PLX I know what you're thinking....just give me $3. Don't do it!! You will miss all the fun. You've waited this long, why not another few months? Not investment advice, maybe a little psychological advice ;)?

2 · Reply

CliffordCapital Feb. 4 at 4:20 PM

$PLX good hedge in the market lol

0 · Reply

madballer Feb. 4 at 4:20 PM

$PLX Going full port on PLX after the 4 week announcement was the best decision I’ve made recently, all the meme stocks are getting completely destroyed while this goes up

1 · Reply

Market Cap	188.19M
Revenue (ttm)	53.40M
Net Income (ttm)	2.93M
EPS (ttm)	N/A
PE Ratio	29.57
Forward PE	11.83
Profit Margin	5.49%
Debt to Equity Ratio	0.00

Volume	1,942,716
Avg Vol	803,414
Day's Range	N/A - N/A
Shares Out	80.42M
Stochastic %K	92%
Beta	-0.25
Analysts	Strong Sell
Price Target	$11.00